SYFe7deccec46914671a9d135c8bd6a44f8

UnknownPhase 1

Bioavailability study with naloxone hydrochloride in healthy...

CCDRD Cooperative Clinical Drug Research and Development AG Source

Compare

Study Type

interventional

Reported enrollment (type unavailable)

N/A

Locations

1 country

Sites

1

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: unknown
Reported enrollment (type unavailable): Not reported
Study completion date: Not reported
Date not reported
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
October 17, 2025
Actual (reported)

Conditions

No therapeutic indication in the current trial with healthy volunteers.

Sponsors & Collaborators

CCDRD Cooperative Clinical Drug Research and Development AG
Industrylead
Vaccpower Limited
Industryco_sponsor

Study Sites (1)

Bed space for short term stay at Diagnostic & Consultative Centre 'Ascendent' Ltd.

Sofia, 1202, Bulgaria

Ivo Bogdanov+35929839494 ivoatbog@gmail.com

Central Study Contacts

Project Manager

+49334223790 contact@ccdrdag.com

Advisor

+447771648715

Study Design

Study Type: interventional
Phase: phase 1

Study Record Dates

First Submitted

October 17, 2025

Source record

Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: 2024-517838-17-00
Data provider: European Medicines Agency (EMA)
Normalization version: ctis-v1

Open registry record

Source retrieved: 2026-10-30 05:46:46 UTC

Locations

BG(1)

SYFca71c33bc66d4ea1855dc692f88042a9

Evaluation of the bioequivalence of two products containing esomeprazole under fasting conditions: Esomeprazole-Syrup 40 mg dose (Test) vs. Nexium 40 mg (Comparator). An open, randomized, single dose, four-period, replicate, crossover trial in healthy volunteers

Phase 1Unknown

SYF18720e83653e4c419f10d58646cac84c

Evaluation of the bioequivalence of two products containing esomeprazole under fed conditions: Esomeprazole-Syrup 40 mg dose (Test) vs. Nexium 40 mg (Comparator). An open, randomized, single dose, four-period, replicate, crossover trial in healthy volunteers

Phase 1Unknown

SYFffaf13a9a9114df7b045f7d41d38485b

Evaluation of bioequivalence of two products containing 50 mg dimenhydrinate: Dimenhydrinate 50 mg (Test) vs. Vomex A 50 mg Lösung zum Einnehmen im Beutel (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers

Phase 1Unknown

SYFce2256bb647d434da75c12fe9d8f48b2

Evaluation of bioequivalence of two products containing 600 mg ibuprofen: Ibuprofen Sopharma 600 mg film-coated tablets (Test) vs. Brufen 600 mg film-coated tablets (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers

Phase 1Unknown

SYF6ed0f8284d8b4f8889b4688057dd752f

Evaluation of bioequivalence of two products containing 400 mg ibuprofen and 100 mg caffeine: Ibuprofen / Caffeine 400 mg / 100 mg coated granules (Test) vs. Thomapyrin TENSION DUO, 400mg / 100mg Filmtabletten (Reference). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers

Phase 1Unknown

SYF03e47ecc0eba45f9bc594971b02e04de

Single dose oral bioequivalence study of Cladribine 10 mg Tablets and Mavenclad® 10 mg tablets (Cladribine) in healthy adult human subjects under fed conditions

Phase 1Unknown

SYFd5b65c77d98d40beb5639ad669fb7568

Evaluation of bioequivalence of two products containing estradiol: Estradiol/INTERMED gel 0.1% w/w (Test) vs. ESTREVA 0.1% gel (Comparator). An open, randomized, single-dose, four-period, full-replicative trial in healthy postmenopausal women

Phase 1Recruiting

lionel@vaccpower.im

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Conditions

Sponsors & Collaborators

Study Sites (1)

Central Study Contacts

Study Design

Study Record Dates

Source record

Locations